CN117860827A - Traditional Chinese medicine composition for treating erythema nodosum and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for treating erythema nodosum and preparation method and application thereof Download PDFInfo
- Publication number
- CN117860827A CN117860827A CN202311783725.8A CN202311783725A CN117860827A CN 117860827 A CN117860827 A CN 117860827A CN 202311783725 A CN202311783725 A CN 202311783725A CN 117860827 A CN117860827 A CN 117860827A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- medicine composition
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 206010015226 Erythema nodosum Diseases 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims description 19
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 208000018631 connective tissue disease Diseases 0.000 claims abstract description 14
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 11
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 11
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 11
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 11
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 11
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 11
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 11
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 11
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 11
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 11
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 9
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 9
- 235000011477 liquorice Nutrition 0.000 claims abstract description 9
- 235000001405 Artemisia annua Nutrition 0.000 claims abstract description 8
- 240000000011 Artemisia annua Species 0.000 claims abstract description 8
- 240000001659 Oldenlandia diffusa Species 0.000 claims abstract description 8
- 241000830536 Tripterygium wilfordii Species 0.000 claims abstract description 8
- 235000015398 thunder god vine Nutrition 0.000 claims abstract description 8
- 240000005001 Paeonia suffruticosa Species 0.000 claims abstract description 4
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims abstract description 4
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 3
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 3
- 229940079593 drug Drugs 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 244000061520 Angelica archangelica Species 0.000 claims description 6
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 241000202726 Bupleurum Species 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 16
- 206010015150 Erythema Diseases 0.000 abstract description 6
- 231100000321 erythema Toxicity 0.000 abstract description 6
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 abstract description 4
- 229960004584 methylprednisolone Drugs 0.000 abstract description 4
- 208000010201 Exanthema Diseases 0.000 abstract description 2
- 201000005884 exanthem Diseases 0.000 abstract description 2
- 206010037844 rash Diseases 0.000 abstract description 2
- 241001092040 Crataegus Species 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 206010047642 Vitiligo Diseases 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 241000212749 Zesius chrysomallus Species 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 240000000774 Cunila origanoides Species 0.000 description 2
- 235000018274 Cunila origanoides Nutrition 0.000 description 2
- 235000014866 Dictamnus albus Nutrition 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- 230000003460 anti-nuclear Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 208000020049 trigeminal nerve disease Diseases 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating erythema nodosum, which is prepared from the following raw materials in parts by weight: 3-15 parts of radix bupleuri, 3-20 parts of sweet wormwood herb, 3-15 parts of Chinese angelica, 3-15 parts of radix angelicae pubescentis, 3-20 parts of cortex lycii radicis, 3-15 parts of notopterygium root, 3-20 parts of fructus kochiae, 3-15 parts of fructus cnidii, 3-20 parts of cortex dictamni, 3-10 parts of liquorice, 3-20 parts of radix salviae miltiorrhizae, 3-15 parts of radix saposhnikoviae, 3-15 parts of tree peony bark, 3-10 parts of honeycomb, 3-12 parts of tripterygium wilfordii, 5-30 parts of hawthorn and 5-30 parts of oldenlandia diffusa. The composition can resolve rash and erythema nodosum, has low recurrence rate and better effect than methylprednisolone commonly used in clinic at present. The invention can effectively treat the nodular erythema related to connective tissue diseases and has clinical popularization and application values.
Description
Technical Field
The invention particularly relates to a traditional Chinese medicine composition for treating erythema nodosum, and a preparation method and application thereof.
Background
Erythema nodosum is a recurrent inflammatory skin disease of complex etiology, and is associated with a variety of factors, such as various pathogenic bacterial infections, and drugs, connective tissue diseases, behcet's disease, etc. Erythema nodosum is usually seen on the extending sides of the lower legs, and is clinically manifested as red or purplish red painful inflammatory nodules, which are good for young and middle-aged women, especially young women, and also have a certain seasonal onset, often seen in spring and autumn. Erythema nodosum caused by connective tissue disease is currently considered to be a delayed hypersensitivity reaction of the body to certain foreign antigens. The connective tissue disease has longer disease course, complex disease condition and high incidence, and the probability of recurrence of erythema nodosum caused by connective tissue disease is high.
At present, the treatment of erythema nodosum is mainly carried out by western medicines, such as antibiotics, non-steroidal anti-inflammatory drugs or glucocorticoids. The related researches on the treatment of traditional Chinese medicines are more, but the effect is not ideal, and most of traditional Chinese medicine formulas are required to be combined with western medicines to have good curative effect. Li Qingsong the effective rate of treating erythema nodosum can reach 90% only by adding flavor with Simiaoyong Antang and simultaneously using the Dragon bead ointment externally. It is necessary to provide a traditional Chinese medicine composition with high safety and few side effects and obvious effect of treating erythema nodosum, especially erythema nodosum related to connective tissue diseases, so as to be used clinically.
Disclosure of Invention
In order to solve the problems, the invention provides a traditional Chinese medicine composition for treating erythema nodosum, which is prepared from the following raw materials in parts by weight:
3-15 parts of radix bupleuri, 3-20 parts of sweet wormwood herb, 3-15 parts of Chinese angelica, 3-15 parts of radix angelicae pubescentis, 3-20 parts of cortex lycii radicis, 3-15 parts of notopterygium root, 3-20 parts of fructus kochiae, 3-15 parts of fructus cnidii, 3-20 parts of cortex dictamni, 3-10 parts of liquorice, 3-20 parts of radix salviae miltiorrhizae, 3-15 parts of radix saposhnikoviae, 3-15 parts of tree peony bark, 3-10 parts of honeycomb, 3-12 parts of tripterygium wilfordii, 5-30 parts of hawthorn and 5-30 parts of oldenlandia diffusa.
Further, the material is prepared from the following raw materials in parts by weight:
6 parts of bupleurum, 9 parts of sweet wormwood, 9 parts of angelica, 10 parts of radix angelicae pubescentis, 10 parts of cortex lycii radicis, 9 parts of notopterygium root, 15 parts of fructus kochiae, 10 parts of fructus cnidii, 12 parts of cortex dictamni, 6 parts of liquorice, 9 parts of radix salviae miltiorrhizae, 9 parts of radix sileris, 12 parts of cortex moutan, 3 parts of nidus vespae, 6 parts of tripterygium wilfordii, 9 parts of hawthorn and 15 parts of oldenlandia diffusa.
Further, the hawthorn is scorched hawthorn fruit.
Further, it is a preparation prepared from fine powder of raw materials or water or organic solvent extract of raw materials as active ingredients, and pharmaceutically acceptable auxiliary materials.
Still further, the formulation is an oral formulation.
Further, the oral preparation is granule, tablet, powder, pill or solution.
The invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps:
(1) Weighing the raw materials according to the proportion;
(2) Grinding the raw materials into powder, or extracting with water or organic solvent, and adding adjuvants or auxiliary components commonly used in medicines.
The invention finally provides application of the traditional Chinese medicine composition in preparing a medicine for treating erythema nodosum.
Further, the medicament is a medicament for treating connective tissue disease-associated erythema nodosum.
The composition takes cortex moutan and radix salviae miltiorrhizae for clearing heat, cooling blood, promoting blood circulation and removing blood stasis, simultaneously takes radix bupleuri and relieving exterior and interior, takes radix tripterygii for promoting blood circulation and removing obstruction in collaterals, dispelling wind and eliminating dampness as principal drugs, takes angelica for nourishing blood and regulating ying, takes cortex lycii radicis for treating wind evil with indefinite exterior, takes cortex dictamni for dispelling wind and eliminating dampness, takes radix sileris pungent powder for dispelling evil as ministerial drugs for assisting with effects of expelling wind and relieving itching, takes fructus cnidii, fructus kochiae, nidus vespae and herba artemisiae annuae for clearing heat and detoxicating, and takes herba oldenlandiae for removing dampness as adjuvant drugs, cooperates with radix angelicae pubescentis and notopterygium root for dispelling wind and eliminating dampness and relieving pain, takes scorched hawthorn for resolving food and invigorating stomach, moves qi and removing blood stasis, takes liquorice for relieving pain and takes medicines as conducing drugs for slowing blood and removing stasis, and dispelling wind and relieving itching.
Clinical experiments prove that: the composition can resolve rash and erythema nodosum, has low recurrence rate and better effect than methylprednisolone commonly used in clinic at present. The invention can effectively treat erythema nodosum, especially the erythema nodosum related to connective tissue diseases, and has clinical popularization and application values.
It should be apparent that, in light of the foregoing, various modifications, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
The above-described aspects of the present invention will be described in further detail below with reference to specific embodiments in the form of examples. It should not be understood that the scope of the above subject matter of the present invention is limited to the following examples only. All techniques implemented based on the above description of the invention are within the scope of the invention.
Detailed Description
The raw materials and equipment used in the specific embodiment of the invention are all known products and are obtained by purchasing commercial products, wherein the modern Chinese medicinal preparation prepared from the Chinese medicinal composition is prepared by a mature preparation process and by referring to the conventional method in the prior art.
EXAMPLE 1 preparation of the medicament of the invention
The formula comprises the following components: 3g of bupleurum, 3g of sweet wormwood, 3g of angelica, 3g of radix angelicae pubescentis, 3g of cortex lycii radicis, 3g of notopterygium root, 3g of fructus kochiae, 3g of fructus cnidii, 3g of cortex dictamni, 3g of liquorice, 3g of radix salviae miltiorrhizae, 3g of radix sileris, 3g of cortex moutan, 3g of nidus vespae, 3g of tripterygium wilfordii, 5g of scorched hawthorn fruit and 5g of oldenlandia diffusa
The preparation method comprises the following steps: weighing the raw materials according to the proportion, adding 10 times of water, decocting for 2 times, each time for 20-30 minutes, filtering, combining the filtrates, concentrating the filtrate under reduced pressure to obtain thick paste, adding common auxiliary materials in medicines, and preparing into tablets.
EXAMPLE 2 preparation of the medicament of the invention
The formula comprises the following components: 15g of bupleurum, 20g of sweet wormwood, 15g of angelica, 15g of radix angelicae pubescentis, 20g of cortex lycii radicis, 15g of notopterygium root, 20g of fructus kochiae, 15g of fructus cnidii, 20g of dittany bark, 10g of liquorice, 20g of radix salviae miltiorrhizae, 15g of radix sileris, 15g of cortex moutan, 10g of nidus vespae, 12g of tripterygium wilfordii, 30g of scorched hawthorn fruit and 30g of oldenlandia diffusa
The preparation method comprises the following steps: weighing the raw materials according to the proportion, adding 10 times of water, decocting for 2 times, each time for 20-30 minutes, filtering, combining the filtrates, concentrating the filtrate under reduced pressure to obtain thick paste, adding common auxiliary materials in medicines, and preparing into granules.
EXAMPLE 3 preparation of the medicament of the invention
The formula comprises the following components: 6g of bupleurum, 9g of sweet wormwood, 9g of angelica, 10g of radix angelicae pubescentis, 10g of cortex lycii radicis, 9g of notopterygium root, 15g of fructus kochiae, 10g of fructus cnidii, 12g of dittany bark, 6g of liquorice, 9g of red sage root, 9g of radix sileris, 12g of tree peony bark, 3g of honeycomb, 6g of tripterygium wilfordii, 9g of scorched hawthorn fruit and 15g of oldenlandia diffusa.
The preparation method comprises the following steps: mixing the above materials with granule (produced by Guangdong party pharmaceutical Co., ltd.).
The advantageous effects of the present invention are described below by way of test examples.
Test example 1 clinical therapeutic Effect of the pharmaceutical composition of the present invention
1. Clinical data
Clinical study cases are derived from nodular erythema patients related to connective tissue diseases of the department of outpatient and hospitalization of the first affiliated hospital of the adult medical college, and are divided into an experimental group and a control group according to a random digital table method, wherein the experimental group is incorporated into 32 cases of male patients, 6 cases of female patients, 26 cases of female patients, the average age of 32.22+/-2.12 years, and the average course of disease of 2.73+/-0.91 years. The control group was included in 27 patients, 8 male patients, 19 female patients, and had an average age of 34.11.+ -. 2.91 years and an average course of 2.77.+ -. 0.69 years.
1.1 diagnostic criteria
(1) Western medicine inclusion criteria:
connective tissue disease uses the U.S. Sharp diagnostic criteria:
1) Main standard
(1) Severe myositis; (2) pulmonary involvement (carbon dioxide dispersion function less than 70%, pulmonary arterial hypertension, pulmonary biopsy showing proliferative vascular injury); (3) reynolds phenomenon/reduced esophageal peristalsis function; (4) swelling of joints, tenderness or hardening of fingers; (5) anti-nuclear antibody positive, titer >1:320, and/or ENA antibody positive.
2) Secondary standard
(1) Alopecia; (2) a decrease in white blood cell count; (3) anemia; (4) pleurisy; (5) pericarditis; (6) arthritis; (7) trigeminal neuropathy; (8) cheek erythema; (9) thrombocytopenia; mild myositis.
3) Diagnosis of the disease
(1) 4 main criteria; (2) serological antinuclear antibodies positive, titre >1:320, except for infectious or neoplastic diseases.
Erythema nodosum was diagnosed by clinical manifestations and pathological biopsies according to Zhu Xuejun, modern diagnostic manual of dermatology (according to typical skin lesions, best before the calf shank, with tenderness, no collapse, combined with skin histopathological examination, as indicated by small She Jiange subcutaneous fat panulitis).
(2) The Chinese medicine incorporates the standard:
the differentiation of erythema nodosum is based on the "Chinese clinical diagnosis and treatment terminology and syndrome type section
1.2 exclusion criteria
(1) Patients with serious diseases of heart, liver, lung, kidney, endocrine and other systems; (2) various infectious agents such as severe upward calling; (3) pregnant or lactating women; (4) the serious illness state may affect the effectiveness and safety of the study. (5) Allergic to the drug ingredients in this study.
2. Therapeutic method
Test group: the patients respectively take the pharmaceutical composition prepared in the embodiment 3 of the invention, and the dosage of each taking is 10-15g; the administration method is warm water infusion, three times a day, 7 days as a treatment course, and 4 treatment courses.
Control group: 8-16mg methylprednisolone is orally administered.
3. Therapeutic effect judgment criterion
According to the guidelines of clinical research on new traditional Chinese medicines, the clinical curative effects are classified into improvement, obvious effect and ineffective.
Improvement: the clinical symptoms (fever, myalgia, arthralgia, red swelling and pain at skin lesions) and signs (pimple, vitiligo, erythema, nodule and local edema) are obviously improved, and the integral reduction rate of the symptoms is more than or equal to 70%;
the effect is shown: the clinical symptoms and signs are improved, and the integral reduction rate of the symptoms is more than or equal to 30 percent;
invalidation: the clinical symptoms are not obviously improved or are obviously aggravated, and the symptom integral reduction rate is less than 30 percent.
Symptom score reduction rate = [ (pre-treatment score-post-treatment score)/pre-treatment score ] ×100%.
The erythema nodosum sign scoring reference (Gao Jinghong et al, university of Anhui university of Chinese medicine, 2016, 35 (05): 29-31.) is specifically scored as follows:
(1) pimple, no pimple, count 0 points; at most 2 papules per square centimeter, 1 point; 3-5 papules per square centimeter, counting 2 points; 6 or more than 6 papules per square centimeter, 3 points.
(2) Vitiligo is no vitiligo, and 0 score is calculated; carefully checking the visible vitiligo, counting 1 minute; immediately finding out vitiligo, counting for 2 minutes; the purple-depressive psychosis is evident, counting 3 minutes.
(3) Red spot, namely, no red spot, counting 0 minutes; slightly pale red, count 1 minute; obvious red spots which are easy to identify are counted for 2 minutes; obvious erythema, count 3 minutes.
(4) The knots are no knots, and 0 score is calculated; the number of the knots is less than or equal to 5, and 1 minute is counted; the number of the knots is more than 5 and less than or equal to 10, and the knots are counted to be 2 minutes; the number of the knots is more than 10 and is counted to be 3 minutes.
(5) The local edema is anhydrous swelling, and the score is 0; local area dermal edema is not easy to palpate, count 1 minute; well-defined dermal edema occurred at multiple sites, counting 2 points; dermal edema and infiltration occurred in a wide area, and were counted as 3 minutes.
4. Therapeutic effects
(1) The results of the clinical efficacy of the pharmaceutical composition of the present invention are shown in table 1. (note: improvement cases are included in the cases of significant effects)
TABLE 1 clinical efficacy results of the pharmaceutical compositions of the invention
| Number of examples | Display effect (example) | Improvement (example) | Invalidation (example) | Effective rate of | |
| Experimental group | 32 | 29 | 26 | 3 | 90.63％ |
| Control group | 27 | 24 | 19 | 3 | 88.89％ |
(2) The recurrence rate of the pharmaceutical composition of the present invention is shown in table 2 following 3 months post-treatment. ( And (3) injection: the recurrence rate is counted from the total parameters and the cases, and the specific calculation formula is recurrence cases/total cases 100% )
TABLE 2 recurrence rate of the pharmaceutical compositions of the invention
| Number of examples | Recurrence (example) | Recurrence rate | |
| Experimental group | 32 | 3 | 9.38％ |
| Control group | 27 | 4 | 14.81％ |
From the statistics of tables 1 and 2, it can be seen that: the pharmaceutical composition has good improvement effect on clinical symptoms of the connective tissue disease-related erythema nodosum, has better effect than methylprednisolone, can effectively treat the connective tissue disease-related erythema nodosum, and prevents recurrence.
In conclusion, the traditional Chinese medicine composition disclosed by the invention is accurate in compatibility, has the effects of cooling blood, removing stasis, dispelling wind, relieving itching, resolving masses and relieving pain, can effectively treat nodular erythema related to connective tissue diseases, is low in recurrence rate, and has clinical popularization and application values.
Claims (9)
1. A traditional Chinese medicine composition for treating erythema nodosum is characterized in that: the composite material is prepared from the following raw materials in parts by weight:
3-15 parts of radix bupleuri, 3-20 parts of sweet wormwood herb, 3-15 parts of Chinese angelica, 3-15 parts of radix angelicae pubescentis, 3-20 parts of cortex lycii radicis, 3-15 parts of notopterygium root, 3-20 parts of fructus kochiae, 3-15 parts of fructus cnidii, 3-20 parts of cortex dictamni, 3-10 parts of liquorice, 3-20 parts of radix salviae miltiorrhizae, 3-15 parts of radix saposhnikoviae, 3-15 parts of tree peony bark, 3-10 parts of honeycomb, 3-12 parts of tripterygium wilfordii, 5-30 parts of hawthorn and 5-30 parts of oldenlandia diffusa.
2. The traditional Chinese medicine composition according to claim 1, wherein: the composite material is prepared from the following raw materials in parts by weight:
6 parts of bupleurum, 9 parts of sweet wormwood, 9 parts of angelica, 10 parts of radix angelicae pubescentis, 10 parts of cortex lycii radicis, 9 parts of notopterygium root, 15 parts of fructus kochiae, 10 parts of fructus cnidii, 12 parts of cortex dictamni, 6 parts of liquorice, 9 parts of radix salviae miltiorrhizae, 9 parts of radix sileris, 12 parts of cortex moutan, 3 parts of nidus vespae, 6 parts of tripterygium wilfordii, 9 parts of hawthorn and 15 parts of oldenlandia diffusa.
3. The traditional Chinese medicine composition according to claim 1 or 2, characterized in that: the fructus crataegi is charred fructus crataegi.
4. The traditional Chinese medicine composition according to claim 1 or 2, characterized in that: the preparation is prepared from fine powder of raw materials or water or organic solvent extract of raw materials as active ingredients and pharmaceutically acceptable auxiliary materials.
5. The traditional Chinese medicine composition according to claim 4, wherein: the preparation is an oral preparation.
6. The traditional Chinese medicine composition according to claim 5, wherein: the oral preparation is granule, tablet, powder, pill or solution.
7. A method for preparing the traditional Chinese medicine composition according to any one of claims 1 to 6, which is characterized in that: it comprises the following steps:
(1) Weighing the raw materials according to the proportion;
(2) Grinding the raw materials into powder, or extracting with water or organic solvent, and adding adjuvants or auxiliary components commonly used in medicines.
8. Use of the traditional Chinese medicine composition according to any one of claims 1-6 in the preparation of a medicament for treating erythema nodosum.
9. Use according to claim 8, characterized in that: the medicine is used for treating connective tissue disease-related erythema nodosum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311783725.8A CN117860827A (en) | 2023-12-22 | 2023-12-22 | Traditional Chinese medicine composition for treating erythema nodosum and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311783725.8A CN117860827A (en) | 2023-12-22 | 2023-12-22 | Traditional Chinese medicine composition for treating erythema nodosum and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117860827A true CN117860827A (en) | 2024-04-12 |
Family
ID=90580309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311783725.8A Pending CN117860827A (en) | 2023-12-22 | 2023-12-22 | Traditional Chinese medicine composition for treating erythema nodosum and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117860827A (en) |
-
2023
- 2023-12-22 CN CN202311783725.8A patent/CN117860827A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101095895B (en) | Externally-used medicament for the sanitation and health-care of female vagina and for treating gynecology vagina diseases and method for making the same | |
| CN112755140B (en) | Pharmaceutical composition for treating gouty arthritis and preparation method and application thereof | |
| CN112138084B (en) | Traditional Chinese medicine composition for treating bronchiectasis qi-yin deficiency and phlegm-heat obstructing lung and application thereof | |
| CN117860827A (en) | Traditional Chinese medicine composition for treating erythema nodosum and preparation method and application thereof | |
| CN114632128A (en) | Collateral-dredging and turbid-removing formula and using method thereof | |
| CN101829188B (en) | Medicament for treating urinary infection and lithiasis | |
| CN105233078A (en) | Traditional Chinese medicine composition for treating viral hepatitis | |
| CN105497262A (en) | Medicine composition for treating liver-yin and kidney-yin deficiency type polycystic ovarian syndrome | |
| CN105362382A (en) | Traditional Chinese medicine composition for treating recurrent oral ulcer and application thereof | |
| CN112138105B (en) | Traditional Chinese medicine composition for treating bronchiectasis lung-spleen qi deficiency and phlegm-damp lung blocking syndrome and application thereof | |
| CN104998158A (en) | Pharmaceutical composition for treating liver cirrhosis and application thereof | |
| CN110478416A (en) | The composition and its preparation method and application for treating rheumatic rheumatoid arthritis | |
| CN113876919B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, pharmaceutical preparation and application thereof | |
| CN108578549B (en) | Medicine for treating acne and application thereof | |
| CN115869376B (en) | Chinese herbal compound composition for treating adult stele disease | |
| CN116270922B (en) | Prescription for eliminating turbid pathogen, resolving masses and removing arthralgia and application thereof | |
| CN112755101B (en) | Traditional Chinese medicine composition for treating knee osteoarthritis and application thereof | |
| CN110876781B (en) | Traditional Chinese medicine composition for treating kidney-yin deficiency type intermenstrual bleeding and night sweat and application thereof | |
| CN102114111B (en) | Medicament for treating damp-heat stagnation type acne | |
| CN105213975A (en) | A kind of pharmaceutical composition and application thereof for the treatment of liver cirrhosis | |
| CN117018131A (en) | Traditional Chinese medicine composition for treating persistent HPV infection and preparation method thereof | |
| CN104644950A (en) | Ointment for treating rheumatoid arthritis and preparation method of ointment | |
| CN104689254A (en) | Traditional Chinese medicine composition for treating psoriasis | |
| CN116920044A (en) | Traditional Chinese medicine composition for postoperative rehabilitation of lung cancer | |
| CN117398439A (en) | Traditional Chinese medicine composition for treating constipation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |